Literature DB >> 28053325

Effects of miRNA-15 and miRNA-16 expression replacement in chronic lymphocytic leukemia: implication for therapy.

G Cutrona1, S Matis1, M Colombo1, C Massucco1, G Baio2, F Valdora1,3, L Emionite4, S Fabris5, A G Recchia6,7, M Gentile6,7, C E Neumaier2, D Reverberi1, R Massara1, S Boccardo8, L Basso9, S Salvi8, F Rosa9, M Cilli4, S Zupo10, M Truini8, P Tassone11, M Calabrese2, M Negrini12, A Neri5,13, F Morabito6,7, F Fais1,3, M Ferrarini14.   

Abstract

Chronic lymphocytic leukemia (CLL) clones are characterized by loss of a critical region in 13q14.3, (del(13)(q14)) involving the microRNA (miRNA) cluster miR-15a and miR-16-1. We have investigated the effects of replacement of miR-15a and miR-16-1. CLL cells transfected with these miRNA mimics exhibited a decrease in cell viability in vitro and impaired capacity for engraftment and growth in NOD/Shi-scid,γcnull (NSG) mice. No synergistic effects were observed when the two miRNA mimics were combined. The phenomena were not restricted to CLL with the del(13)(q14) lesion. Similar effects induced by miRNA mimics were seen in cells with additional chromosomal abnormalities with the exception of certain CLL clones harboring TP53 alterations. Administration of miRNA mimics to NSG mice previously engrafted with CLL clones resulted in substantial tumor regression. CLL cell transfection with miR-15a and miR-16-1-specific inhibitors resulted in increased cell viability in vitro and in an enhanced capacity of the engrafted cells to grow in NSG mice generating larger splenic nodules. These data demonstrate that the strong control by miR-15a and miR-16-1 on CLL clonal expansion is exerted also at the level of full-blown leukemia and provide indications for a miRNA-based therapeutic strategy.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28053325     DOI: 10.1038/leu.2016.394

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  53 in total

1.  High-throughput sequencing for the identification of NOTCH1 mutations in early stage chronic lymphocytic leukaemia: biological and clinical implications.

Authors:  Marta Lionetti; Sonia Fabris; Giovanna Cutrona; Luca Agnelli; Carmela Ciardullo; Serena Matis; Gabriella Ciceri; Monica Colombo; Francesco Maura; Laura Mosca; Massimo Gentile; Anna G Recchia; Fiorella Ilariucci; Caterina Musolino; Stefano Molica; Francesco Di Raimondo; Agostino Cortelezzi; Davide Rossi; Gianluca Gaidano; Fortunato Morabito; Manlio Ferrarini; Antonino Neri
Journal:  Br J Haematol       Date:  2014-03-02       Impact factor: 6.998

2.  microRNAome expression in chronic lymphocytic leukemia: comparison with normal B-cell subsets and correlations with prognostic and clinical parameters.

Authors:  Massimo Negrini; Giovanna Cutrona; Cristian Bassi; Sonia Fabris; Barbara Zagatti; Monica Colombo; Manuela Ferracin; Lucilla D'Abundo; Elena Saccenti; Serena Matis; Marta Lionetti; Luca Agnelli; Massimo Gentile; Anna Grazia Recchia; Sabrina Bossio; Daniele Reverberi; Gianmatteo Rigolin; George A Calin; Silvia Sabbioni; Giandomenico Russo; Pierfrancesco Tassone; Fortunato Morabito; Manlio Ferrarini; Antonino Neri
Journal:  Clin Cancer Res       Date:  2014-06-10       Impact factor: 12.531

3.  Gene dosage effects in chronic lymphocytic leukemia.

Authors:  Ludger Sellmann; Rene Scholtysik; Markus Kreuz; Sandra Cyrull; Enrico Tiacci; Jens Stanelle; Alexander Carpinteiro; Holger Nückel; Tanja Boes; Stefan Gesk; Reiner Siebert; Ludger Klein-Hitpass; Ulrich Dührsen; Jan Dürig; Ralf Küppers
Journal:  Cancer Genet Cytogenet       Date:  2010-12

4.  Abnormal microRNA-16 locus with synteny to human 13q14 linked to CLL in NZB mice.

Authors:  Elizabeth S Raveche; Erica Salerno; Brian J Scaglione; Vijaya Manohar; Fatima Abbasi; Yi-Chu Lin; Torgny Fredrickson; Pablo Landgraf; Sumant Ramachandra; Konrad Huppi; Jorge R Toro; Vincent E Zenger; Robert A Metcalf; Gerald E Marti
Journal:  Blood       Date:  2007-03-09       Impact factor: 22.113

5.  Karyotype-specific microRNA signature in chronic lymphocytic leukemia.

Authors:  Rosa Visone; Laura Z Rassenti; Angelo Veronese; Cristian Taccioli; Stefan Costinean; Baltazar D Aguda; Stefano Volinia; Manuela Ferracin; Jeff Palatini; Veronica Balatti; Hansjuerg Alder; Massimo Negrini; Thomas J Kipps; Carlo M Croce
Journal:  Blood       Date:  2009-08-28       Impact factor: 22.113

6.  The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia.

Authors:  Ulf Klein; Marie Lia; Marta Crespo; Rachael Siegel; Qiong Shen; Tongwei Mo; Alberto Ambesi-Impiombato; Andrea Califano; Anna Migliazza; Govind Bhagat; Riccardo Dalla-Favera
Journal:  Cancer Cell       Date:  2010-01-07       Impact factor: 31.743

7.  Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy.

Authors:  Carmen Diana Herling; Marion Klaumünzer; Cristiano Krings Rocha; Janine Altmüller; Holger Thiele; Jasmin Bahlo; Sandra Kluth; Giuliano Crispatzu; Marco Herling; Joanna Schiller; Anja Engelke; Eugen Tausch; Hartmut Döhner; Kirsten Fischer; Valentin Goede; Peter Nürnberg; Hans Christian Reinhardt; Stephan Stilgenbauer; Michael Hallek; Karl-Anton Kreuzer
Journal:  Blood       Date:  2016-05-25       Impact factor: 22.113

8.  Defective DROSHA processing contributes to downregulation of MiR-15/-16 in chronic lymphocytic leukemia.

Authors:  D Allegra; V Bilan; A Garding; H Döhner; S Stilgenbauer; F Kuchenbauer; D Mertens; M Zucknick
Journal:  Leukemia       Date:  2013-08-26       Impact factor: 11.528

Review 9.  Small silencing RNAs: an expanding universe.

Authors:  Megha Ghildiyal; Phillip D Zamore
Journal:  Nat Rev Genet       Date:  2009-02       Impact factor: 53.242

10.  Role of mir-15a/16-1 in early B cell development in a mouse model of chronic lymphocytic leukemia.

Authors:  Chingiz Underbayev; Siddha Kasar; William Ruezinsky; Heba Degheidy; Joel Solomon Schneider; Gerald Marti; Steven R Bauer; Diego Fraidenraich; Marilyn M Lightfoote; Vijay Parashar; Elizabeth Raveche; Mona Batish
Journal:  Oncotarget       Date:  2016-09-20
View more
  14 in total

1.  Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations.

Authors:  Benjamin H Durham; Bartlomiej Getta; Sascha Dietrich; Justin Taylor; Helen Won; James M Bogenberger; Sasinya Scott; Eunhee Kim; Young Rock Chung; Stephen S Chung; Jennifer Hüllein; Tatjana Walther; Lu Wang; Sydney X Lu; Christopher C Oakes; Raoul Tibes; Torsten Haferlach; Barry S Taylor; Martin S Tallman; Michael F Berger; Jae H Park; Thorsten Zenz; Omar Abdel-Wahab
Journal:  Blood       Date:  2017-08-11       Impact factor: 22.113

2.  Loss of miR-16 contributes to tumor progression by activation of tousled-like kinase 1 in oral squamous cell carcinoma.

Authors:  Shousen Hu; Honghan Wang; Dan Yan; Wuhao Lu; Pei Gao; Weihua Lou; Xiangzhen Kong
Journal:  Cell Cycle       Date:  2018-10-09       Impact factor: 4.534

3.  Interferon regulatory factor 1 (IRF-1) downregulates Checkpoint kinase 1 (CHK1) through miR-195 to upregulate apoptosis and PD-L1 expression in Hepatocellular carcinoma (HCC) cells.

Authors:  Yihe Yan; Leting Zheng; Qiang Du; Xiao Cui; Kun Dong; Yarong Guo; David A Geller
Journal:  Br J Cancer       Date:  2021-03-26       Impact factor: 7.640

4.  LINC00152 expression in normal and Chronic Lymphocytic Leukemia B cells.

Authors:  Serena Matis; Martina Rossi; Lorenzo Brondolo; Martina Cardillo; Daniele Reverberi; Rosanna Massara; Monica Colombo; Adalberto Ibatici; Emanuele Angelucci; Tiziana Vaisitti; Silvia Bruno; Sonia Fabris; Antonino Neri; Massimo Gentile; Fortunato Morabito; Giovanna Cutrona; Paola Briata; Roberto Gherzi; Franco Fais
Journal:  Hematol Oncol       Date:  2021-10-28       Impact factor: 4.850

Review 5.  MicroRNAs in Autoimmunity and Hematological Malignancies.

Authors:  Mirco Di Marco; Alice Ramassone; Sara Pagotto; Eleni Anastasiadou; Angelo Veronese; Rosa Visone
Journal:  Int J Mol Sci       Date:  2018-10-12       Impact factor: 5.923

6.  Prognostic implications of decreased microRNA-101-3p expression in patients with non-small cell lung cancer.

Authors:  Hai-Min Lu; Wan-Wan Yi; Yu-Shui Ma; Wei Wu; Fei Yu; Heng-Wei Fan; Zhong-Wei Lv; Hui-Qiong Yang; Zheng-Yan Chang; Chao Zhang; Wen-Ting Xie; Jun-Jian Jiang; Ying-Chun Song; Li Chai; Cheng-You Jia; Gai-Xia Lu; Xiao-Jun Zhong; Li-Kun Hou; Chun-Yan Wu; Min-Xin Shi; Ji-Bin Liu; Da Fu
Journal:  Oncol Lett       Date:  2018-10-09       Impact factor: 2.967

7.  Prognostic Value of MicroRNA-15a in Human Cancers: A Meta-Analysis and Bioinformatics.

Authors:  Fei-Ran Yang; Hui-Jie Li; Ting-Ting Li; Yu-Feng Zhao; Zong-Kai Liu; Xiu-Rong Li
Journal:  Biomed Res Int       Date:  2019-04-02       Impact factor: 3.411

8.  STAT5-dependent regulation of CDC25A by miR-16 controls proliferation and differentiation in FLT3-ITD acute myeloid leukemia.

Authors:  Gabrielle Sueur; Alison Boutet; Mathilde Gotanègre; Véronique Mansat-De Mas; Arnaud Besson; Stéphane Manenti; Sarah Bertoli
Journal:  Sci Rep       Date:  2020-02-05       Impact factor: 4.379

Review 9.  miRNAs in NK Cell-Based Immune Responses and Cancer Immunotherapy.

Authors:  Silvia Pesce; Marco Greppi; Elisa Ferretti; Valentina Obino; Simona Carlomagno; Mariangela Rutigliani; Fredrik B Thoren; Simona Sivori; Patrizio Castagnola; Simona Candiani; Emanuela Marcenaro
Journal:  Front Cell Dev Biol       Date:  2020-02-25

10.  Functional Activation of Osteoclast Commitment in Chronic Lymphocytic Leukaemia: a Possible Role for RANK/RANKL Pathway.

Authors:  Cecilia Marini; Silvia Bruno; Francesco Fiz; Cristina Campi; Roberta Piva; Giovanna Cutrona; Serena Matis; Alberto Nieri; Maurizio Miglino; Adalberto Ibatici; Anna Maria Orengo; Anna Maria Massone; Carlo Emanuele Neumaier; Daniela de Totero; Paolo Giannoni; Matteo Bauckneht; Michele Pennone; Claudya Tenca; Elena Gugiatti; Alessandro Bellini; Anna Borra; Elisabetta Tedone; Hülya Efetürk; Francesca Rosa; Laura Emionite; Michele Cilli; Davide Bagnara; Valerio Brucato; Paolo Bruzzi; Michele Piana; Franco Fais; Gianmario Sambuceti
Journal:  Sci Rep       Date:  2017-10-26       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.